Zouki Dionysia MEDICAL ONCOLOGY

• PhD, “Research in colorectal cancer with mismatch repair deficiency”, Medical School of Athens, 1st Department of Pathology, National and Kapodistrian University, Greece

• European Society for Medical Oncology (ESMO)

• Hellenic Society of Medical Oncology (HeSMO)

• Hellenic Group of Young Oncologists (HeGYO)

Editorial Boards

• Peer reviewer for scientific international journals indexed in PubMed

– Current Molecular Pharmacology, Bentham Science (BMS-CMP)

-Spandidos Publications academic journals

• 2023 – up to date: Hygeia Hospital, Medical Oncologist.

• 2022-2023: training in Breast Cancer Unit, University College London Hospitals NHS Foundation Trust, London, England, within the context of Oncology Residency as scholarship holder from Hellenic Society of Medical Oncology (HeSMO).

• 2020-2023: Second Department of Medical Oncology “Agios Savvas” Cancer Hospital.

-Medical Oncology: training and participation in clinical and scientific activities in medical oncology at Second Department of Medical Oncology “Agios Savvas” Cancer Hospital, within the context of Oncology Residency.

• 2019-2020: First Department of Pathology, Medical School, National and Kapodistrian University of Athens.

-Immunohistochemical analysis of molecular pathways in colorectal carcinomas: design of the experimental procedure, immunohistochemical staining of tissue samples for certain and significant cancer-related proteins, careful evaluation and registration of data, statistical analysis, within the context of my doctoral thesis.

-Member of the National Network of Precision Medicine in Oncology:  Identify the molecular profile in solid tumors and hematologic malignancies in the context of individualized and targeted therapy of each patient, collection of biological material and the associated data to form a biobank for hematologic malignancies.

• 2015-2018: Internal Medicine Hospital of Athens –Spiliopouleio, Agia Eleni: Specialization in Internal Medicine.

-Internal Medicine: 3 years training and participation in clinical activities in internal medicine at “Internal Medicine Hospital of Athens –Spiliopouleio, Agia Eleni, within the context of Oncology Residency.

-Hematology: 6 months training and participation in laboratory /medical activities of the Hematology Department at General Hospital of Athens “Laiko”, University of Athens, within the context of Oncology Residency.

• 2014- 2015: Rural General Doctor, Remote regional Clinic “Agia Sofia”, Psachna Health Medical Center and Cardiology Clinic at General Hospital of Chalkida, Evoia, Greece.

Clinical Interest

Clinical experience in medical oncology and care of patients with solid malignancies.

Research Interest

Participation as sub-investigator in international clinical studies for breast and lung cancer.

• Graduate of the Hellenic Academy of Oncology (EAKO) – 7th cycle of studies, awarded for the excellent performance in the final exams.

• Scholarship holder from the Hellenic Society of Medical Oncology (HeSMO) for training in Breast Cancer Unit, University College London Hospitals NHS Foundation Trust, London, England.

Co-author in the English book titled “Clinical Genitourinary Pathology: A case – based learning Approach”, Springer International Publishing

George Agrogiannis, Christos Alamanis, Eleni A. Karatrasoglou, Georgios Kousournas, Andreas C. Lazaris, Vasileios Spapis, Georgia-Eleni Thomopoulou & Dionysia N. Zouki.

eBook ISBN 978-3-319-72194-1 Published: 13 July 2018

• 2023:” Male breast cancer survival data and clinicopathological characteristics: A single-centre experience”, J Clin Oncol 41, 2023 (suppl 16; abstr e18837), doi: 10.1200/JCO.2023.41.16_suppl.e18837. 

• 2023: “Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data”, Annals of Oncology, Volume 34, S98, doi: https://doi.org/10.1016/j.annonc.2023.04.289.

• 2022: “Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR (+), HER-2 (-) metastatic breast cancer”, J Clin Oncol 40, 2022 (suppl 16; abstr e13034), doi: 10.1200/JCO.2022.40.16_suppl.e13034

• 2022: “Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study”, Annals of Oncology, Volume 33, S300, doi: https://doi.org/10.1016/j.annonc.2022.04.232

• 2022: “Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer”, Int J Oncol. 2022 Mar;60(3):31. doi: 10.3892/ijo.2022.5321. Epub 2022 Feb 16.

• 2022: “Nivolumab‑induced lichenoid granulomatous stomatitis in a patient with advanced melanoma: A case report”, Molecular and Clinical Oncology, 16, 79. https://doi.org/10.3892/mco.2022.2512

• 2022: “Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review”, Cancers (Basel). 2022 Jan 10;14(2):330. doi:  10.3390/cancers14020330.

• 2021: “MTOR/4EBP1 signaling and MMR status in colorectal cancer: New correlations and arising perspectives”, Pathol Res Pract. 2021 Dec; 228:153655. doi: 10.1016/j.prp.2021.153655. Epub 2021 Oct 15.

• 2021: “Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy”, Case Rep Oncol. 2021 Jul 1;14(2):1059-1065. doi: 10.1159/000516035.

• 2021: “Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review”, BMC Gastroenterol. 2021 May 19;21(1):227. doi: 10.1186/s12876-021-01812-7.